Benign Breast Disease: Toward Molecular Prediction of Breast Cancer Risk
Abstract
The purpose of this Center of Excellence is to bring molecular risk prediction for breast cancer into the clinical arena. Our specific aims are to establish a tissue repository from a retrospective cohort of women with benign breast disease (BBD) to identify those who developed breast cancer (cases) and those who did not (controls); to test potential biomarkers of risk in this archival tissue set; and to discover new, potentially relevant biomarkers of risk in fresh and frozen specimens of BBD. We are completing follow-up on a retrospective cohort of 12,000 women with BBD diagnosed at Mayo Clinic between 1967 and 1991. We anticipate identifying approximately 700 cases and we will match appropriate controls to those cases. We have demonstrated excellent participation rates and access to benign tissues from cases and controls. We have information on established risk factors, permitting independent evaluation of the molecular markers. Upon finalization of all Human Subjects issues (approval still pending at Wayne State), we will initiate collection of fresh BBD samples for the discovery phase of our work.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 01, 2003
- Accession Number
- ADA418667
Entities
People
- Lynn C. Hartmann
Organizations
- Mayo Clinic